Wednesday, June 10, 2026

pharma Β· Knee Osteoarthritis Β· Hypoplastic Left Heart Syndrome Β· RGBP

Regeneron Ireland Designated

Regeneron Ireland Designated clinical programs β€” 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

LA MESA, CA, IE HQ
Public company Type
RGBP Β· NYSE Ticker
Company details
Status
Public
HQ
LA MESA, CA, IE
Programs
10
Drugs
62
Patents
8292
Intelligence Β· Clinical Programs

Regeneron Ireland Designated projects

2 ClinicalTrials.gov programs sponsored by Regeneron Ireland Designated.

Regeneron Ireland Designated has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Cellular Matrix / A-CP-HA Kit

    Regeneron Ireland Designated Activity Company (DAC)

    Genitourinary Syndrome of Menopause

    approved small molecule active

    1 trial
  2. hyaluronic Acid + platelet-rich plasma

    Regeneron Ireland Designated Activity Company (DAC)

    Knee Osteoarthritis

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Regeneron Ireland Designated have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.